{"id":"W4389233901","doi":"10.1182/blood-2023-181792","title":"Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in <i>FLT3</i>-ITD/ <i>NPM1</i>wt Patients - a Study By the NOPHO-DB-SHIP Consortium","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Gemtuzumab ozogamicin; Internal medicine; Oncology; Clinical trial; Phases of clinical research; Induction chemotherapy; Transplantation; Chemotherapy; Surgery; Stem cell; CD34; CD33","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00268305,0.001789218,0.001566397,0.0004151371,0.0005969293,0.001791665,0.001527092,0.001948425,0.02090754],"category_scores_gemma":[0.002018605,0.0005876682,0.001497757,0.0003511173,0.0009956619,0.001071124,0.001065544,0.003883659,0.004538442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001318228,"about_ca_system_score_gemma":0.003613173,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007175913,"about_ca_topic_score_gemma":0.002419855,"domain_scores_codex":[0.9991049,0.0004390361,0.00003511438,0.0001398776,0.0001092692,0.0001717698],"domain_scores_gemma":[0.9987128,0.0001450578,0.0002618351,0.0001369697,0.00009332651,0.00065002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6766403,0.03307337,0.003198802,0.003151922,0.00173091,0.0004127162,0.0003270504,0.005080358,0.03094976,0.005682975,0.08366052,0.1560913],"study_design_scores_gemma":[0.8661492,0.0742237,0.004617356,0.000189631,0.0004496138,0.0002948082,0.00005176581,0.001839696,0.003560677,0.00183549,0.04674004,0.00004803186],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.5997346,0.009318078,0.01493981,0.007793992,0.002159538,0.2501825,0.05280681,0.003241186,0.0598234],"genre_scores_gemma":[0.5169225,0.006178426,0.02617939,0.01469343,0.001125035,0.34386,0.04252084,0.0005203873,0.04799997],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.02090754,"threshold_uncertainty_score":0.06994271,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1196856919884483,"score_gpt":0.4213169335338411,"score_spread":0.3016312415453928,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}